ロード中...
Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6592894/ https://ncbi.nlm.nih.gov/pubmed/31239473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-45539-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|